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Background: Diastolic dysfunction is a major cause of heart failure (HF) with a preserved ejection fraction
(HFpEF); however, there is no clear strategy for treating diastolic dysfunction. Myocardial and vascular
abnormalities may cause HFpEF, which indicates that correcting both abnormalities may speciﬁcally
improve the severity of diastolic dysfunction. Candesartan primarily affects the myocardium, but
azilsartan affects the myocardium and the aortic vasculature. This study was undertaken to test the
hypothesis that azilsartan, but not candesartan, improves left ventricular (LV) diastolic dysfunction in
patients with hypertension and HFpEF.
Methods: Among patients with HF in our database, the patients who received azilsartan or candesartan
were retrospectively screened. Fifteen patients treated with azilsartan were identiﬁed, and sex-matched
patients who received candesartan were blindly selected.
Results: At baseline, there were no signiﬁcant differences between the two groups in clinical ﬁndings,
echocardiographic parameters, and plasma brain natriuretic peptide levels. At 3e6 months, blood
pressure decreased to similar levels in both groups. However, the early LV ﬁlling velocity/early diastolic
velocity (E/e0) ratio decreased in the azilsartan group (13.0 ± 4.2 vs. 10.9 ± 3.2, p ¼ 0.03), but remained
unchanged in the candesartan group (12.0 ± 3.6 vs. 12.5 ± 5.0, p ¼ 0.58; for interaction, p ¼ 0.04). Other
echocardiographic parameters were unaltered by azilsartan or candesartan.
Conclusion: Azilsartan improves diastolic function in HF patients with hypertension, and it may be the
preferred option over other angiotensin II receptor blockers in patients with HFpEF.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
The primary focus of research on cardiac diastolic dysfunction
is to understand the pathophysiology of heart failure (HF)
because HF with a preserved ejection fraction (HFpEF) is as
aggressive as HF with a reduced ejection fraction (HFrEF). Despite
current medical therapy of angiotensin-converting enzyme in-
hibitors or b-adrenergic receptor blockers for patients with
HFrEF1e3, no obvious evidence-based drugs or even potentialthis paper that there are no
onﬂict of interest.
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tric Emergency & Critical Care Metherapeutic candidates have been identiﬁed for treating patients
with HFpEF. Heart failure with a preserved ejection fraction is
primarily attributable to left ventricular (LV) diastolic dys-
function1e4. Abnormalities in the LV myocardium such as
myocardial hypertrophy, myocardial ﬁbrosis, and LV geometrical
changes are largely involved in both types of HF; in addition,
endothelial dysfunction and abnormalities in aortic vessel prop-
erties such as aortic capacitance or resistance are involved in
HFpEF4,5. In short, HFrEF is primarily caused by a myocardial
abnormality, whereas HFpEF is primarily attributable to abnor-
malities in the myocardium and in the aortic vessels. Elzinga and
Westerhof6 showed that changes in aortic impedance or
capacitance largely modulate the time of ejection onset: a low
compliance of aortic vasculature hastens the time of aortic
opening and, consequently, the time of LV ejection onset. We








Number of patients 15 15
Background
Age, y 74 ±11 68 ±13 0.17
Male, n (%) 10 (67) 10 (67) > 0.99
Height, cm 159 ±9 165 ±11 0.18
Body weight, kg 59 ±16 69 ±17 0.09
BMI 23 ±4 25 ±4 0.10
Systolic blood pressure, mmHg 140 ±15 141 ±13 0.86
Diastolic blood pressure, mmHg 81 ±9 80 ±10 0.76
Heart rate, bpm 76 ±13 70 ±9 0.21
Baseline disease, n (%)
Hypertensive heart disease 10 (67) 5 (33) 0.07
Ischemic heart disease 1 (7) 3 (20) 0.28
Dilated cardiomyopathy 1 (7) 4 (27) 0.14
Hypertrophic cardiomyopathy 1 (7) 0 (0) 0.31
Valvular disease 2 (13) 3 (20) 0.62
Coadministrative drugs
Ca channel blockers 3 (20) 1 (7) 0.28
ACE inhibitors 1 (7) 1 (7) > 0.99
Alpha2-agonists 1 (7) 0 (0) 0.31
Beta-blockers 0 (0) 3 (20) 0.07
Values are presented as the mean ± the standard deviation or n (%), as appropriate.
ACE ¼ angiotensin converting enzyme; BMI ¼ body-mass index; Ca ¼ calcium.
M. Sakamoto et al.202characterized by an increase in aortic capacitance, increases the
LV relaxation rate in canine models7,8. These considerations
indicate that an improvement in cardiac dysfunction and vessel
dysfunction is essential to improve LV diastolic dysfunction
because cardiac improvement such as myocardial ﬁbrosis may
shift the LV diastolic pressureevolume relationship to the right,
and an improvement in aortic arterial capacitance may increase
the speed of the LV relaxation rate9. Azilsartan, a new type of
angiotensin receptor blocker (ARB), was recently shown to largely
affect the arterial vasculature and the myocardium10. This ﬁnding
endorses the hypothesis that azilsartan improves LV diastolic
dysfunction in patients with HFpEF.
The present study tested the hypothesis that azilsartan
decreases the ratio of the early LV ﬁlling velocity (E) and the early
diastolic velocity (e0) of the mitral valve annulus (LV E/e0), which
is the diastolic property obtained on an echocardiogram of HFpEF
patients with hypertension9. We also observed the early diastolic
velocity of the mitral valve annulus (e0). We also compared
the effects of azilsartan with the effects of candesartan, which
has a chemical structure similar to azilsartan but fewer vascular
effects.
2. Methods
2.1. Statement of ethics
This study was approved by the National Cerebral and Cardio-
vascular Center Research Ethics Committee (Suita, Japan). The
Committee decided that acquisition of informed consent from the
30 selected patients was not required, based on the Japanese
Clinical Research Guidelines, because it was a retrospective obser-
vational study. A public announcement was instead published in
accordance with the request of the Ethics Committee and the
Guidelines.
2.2. Study population and protocols
We enrolled HFpEF patients with hypertension who were
treated with azilsartan and had undergone echocardiography
before and after treatment. In our database of 3082 patients treated
during 2011e2014, we found 15 patients who matched these
criteria. We only found 15 patients in our database who were
treated with azilsartan because it was recently launched in Japan
and is only permitted to treat patients with hypertension. Using the
same database, we also randomly selected 15 HFpEF patients with
hypertension who were treated with candesartan and had under-
gone echocardiography before and after treatment. Clinical
parameters and plasma brain natriuretic peptide (BNP) levels were
recorded in addition to echocardiograms of all patients.
2.3. Echocardiography
We retrospectively reviewed the echocardiography data of the
enrolled patients by using their medical records. The LV
dimensions, left atrial volume, and wall thickness were measured
in accordance with the American Society of Echocardiography
Guidelines11. The LV ejection fraction (LVEF) was measured using
the Simpson biplane method or the semiquantitative two-
dimensional visual estimate method, as previously described12.
The LV end-diastolic volume and mass were calculated using the
Teichholz formula and Devereux formula13,14, respectively. We
obtained the early (E) and late (A) LV ﬁlling velocities of the
mitral inﬂow and the E-wave deceleration time (DcT) from
Doppler methods, and we recorded the ratio of the E-wave to A-
wave (E/A ratio). We also recorded the LV E/e0 ratio, according toa previous report. The sample volume of pulsed-wave Doppler
imaging was placed at the tip level of the mitral leaﬂets in the
apical four-chamber view. On the Doppler tracing, the diastolic
signal shows a negative deﬂection. Similar to conventional
Doppler of mitral inﬂow, we deﬁned the E-wave and an A-wave,
measured the peak early and late LV ﬁlling velocities, and then
used the average values of septal and lateral velocities as e0 and
a0, respectively12,15.2.4. Statistical analysis
All statistical analyses were performed using JMP 11 software
(SAS Institute Inc., Cary, NC, USA). The data are expressed as the
mean ± the standard error. The Student t test was used to compare
data between the two groups. Multiple comparisons were con-
ducted by one-way analysis of variance (ANOVA) with Bonferroni's
post hoc test. All values of p < 0.05 were considered statistically
signiﬁcant.3. Results
As shown in Table 1, the background characteristics of patients
such as age was similar in both groups. There were no signiﬁcant
differences between the two groups in baseline diseases and type of
drugs used. As shown in Tables 2 and 3, blood pressure, plasma BNP
levels, and echocardiographic parameters at baseline and 3e6
months after treatment were similar in the azilsartan and cande-
sartan groups. The heart rate was slightly reduced after treatment
with azilsartan but not with candesartan. This may be attributable
to the effects of coadministered drugs such as calcium (Ca) channel
blockers or to the direct effects of azilsartan. There were no differ-
ences between the two groups in echocardiographic parameters at
baseline, and candesartan did not affect these parameters 3e6
months after treatment. However, azilsartan signiﬁcantly decreased
LV septal, lateral, and, consequently, average E/e0 values at 3e6
months. The changes in the average E/e0 value are shown in Figure 1.
Table 2







Systolic blood pressure, mmHg 140 ±15 124 ±15 <0.01*
Diastolic blood pressure, mmHg 81 ±9 70 ±9 <0.01*
Heart rate, bpm 76 ±13 68 ±6 0.04*
Echocardiographic parameters
IVS, mm 9.8 ±1 9.7 ±3 0.92
PW, mm 9.9 ±1 9.9 ±3 0.93
LVDd, mm 51 ±10 49 ±9 0.11
LVDs, mm 35 ±10 32 ±9 0.13
LVEF, % 56 ±15 57 ±14 0.65
LAd, mm 39 ±6 39 ±6 0.90
LAVi, mL/m2 64 ±30 57 ±32 0.19
TMF E, cm/s 71 ±23 75 ±35 0.49
TMF A, cm/s 86 ±22 84 ±22 0.58
TMF E/A 0.77 ±0.3 0.78 ±0.3 0.94
TMF DcT, ms 228 ±53 219 ±41 0.55
LV septal E/e0 15.2 ±6.2 13.4 ±4.7 0.03*
LV lateral E/e0 11.5 ±4.1 9.3 ±2.6 0.02*
Average LV E/e0 13.0 ±4.2 10.9 ±3.2 0.03*
Biomarker
Plasma BNP levels, pg/mL 173 ±32 113 ±21 0.048*
A ¼ the late (A) left ventricular ﬁlling velocity; BNP ¼ brain natriuretic peptide;
DcT¼ deceleration time; E¼ early left ventricular ﬁlling velocity; e0 ¼ early diastolic
velocity; IVS ¼ interventricular septum; LAd ¼ left atrium diameter; LAVi ¼ left
atrial volume index; LV ¼ left ventricular; LVDd ¼ left ventricular diameter at end
diastole; LVDs ¼ left ventricular diameter at end systole; LVEF ¼ left ventricular
ejection fraction; W ¼ posterior wall; TMF ¼ transmitral ﬂow.
The values in the table are presented as the mean ± the standard deviation or n (%),
as appropriate.
* Indicates a signiﬁcant value, p < 0.05.
a The p values are based on analysis of variance (ANOVA), as appropriate.
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Systolic blood pressure, mmHg 141 ±13 130 ±14 <0.01*
Diastolic blood pressure, mmHg 80 ±10 75 ±8 <0.01*
Heart rate, bpm 70 ±9 69 ±10 0.16
Echocardiographic parameter
IVS, mm 9.7 ±2 9.5 ±3 0.75
PW, mm 9.6 ±1 9.3 ±2 0.63
LVDd, mm 55 ±10 54 ±11 0.59
LVDs, mm 38 ±13 37 ±13 0.43
LVEF, % 49 ±16 50 ±17 0.56
LAd, mm 42 ±7 43 ±10 0.48
LAVi, mL/m2 52 ±15 47 ±23 0.41
TMF E, cm/s 62 ±23 57 ±23 0.51
TMF A, cm/s 67 ±21 70 ±26 0.18
TMF E/A 0.99 ±0.4 0.94 ±0.5 0.68
TMF DcT, ms 215 ±78 197 ±56.0 0.34
LV septal E/e0 12.6 ±3.5 12.7 ±3.9 0.90
LV lateral E/e0 12.2 ±4.6 12.7 ±6.4 0.68
Average LV E/e0 12.0 ±3.6 12.5 ±5.0 0.58
Biomarker
Plasma BNP levels, pg/mL 171 ±28 116 ±19 0.10
BNP ¼ brain natriuretic peptide; E ¼ early left ventricular ﬁlling velocity; e0 ¼ early
diastolic velocity; IVS ¼ interventricular septum; LAd ¼ left atrium diameter;
LAVi ¼ left atrial volume index; LV ¼ left ventricular; LVDd ¼ left ventricular
diameter at end diastole; LVDs¼ left ventricular diameter at end systole; LVEF¼ left
ventricular ejection fraction; PW ¼ posterior wall; TMF ¼ transmitral ﬂow;
DcT ¼ deceleration time.
The values in the table are presented as the mean ± the SD or n (%), as appropriate.
* Indicates a signiﬁcant value, p < 0.05.
a The p values are based on analysis of variance (ANOVA), as appropriate.
Azilsartan affects the diastolic function 2034. Discussion
In the present study, we demonstrated that the LV E/e0 ratio
substantially decreased in the azilsartan group, but not in the
candesartan group. This ﬁnding demonstrated that azilsartan im-
proves LV diastolic function in HF patients with systemic
hypertension.Figure 1. The E/e0 values of the patients before medication are plotted as circles, and
the E/e0 values of 3e6 months after medication are plotted as squares. E ¼ early left
ventricular ﬁlling velocity; e0 ¼ early diastolic velocity; ns ¼ not signiﬁcant.4.1. Angiotensin receptor blockers for patients with HF
Angiotensin receptor blockers are effective for treating patients
with HF16,17. Candesartan improves clinical outcomes in patients
with HFrEF18, even with angiotensin-converting enzyme in-
hibitors17. This effect has also been demonstrated with valsartan19.
However, there is no clear consensus onwhether ARBs are effective
for patients with HFpEF. The Irbesartan in Heart Failure with Pre-
served Systolic Function (I-PRESERVE) trial showed that irbesartan
did not improve the clinical outcomes of HFpEF patients20, and the
Candesartan in Heart FailureeAssessment of Mortality and
Morbidity (CHARM)-Preserved trial showed the ineffectiveness of
candesartan in HF patients with a moderately preserved ejection
fraction, although the p value for improvement in the cardiac
clinical outcome was 0.05121. The present study also had similar
ﬁndings: there was no improvement in LV diastolic dysfunction in
HF patients with hypertension and a decreased LV E/e0 ratio. Can-
desartan decreased plasma BNP levels to levels comparable with
the levels in the azilsartan group, which suggests that the cardiac
load was decreased with a consequent decrease in the extent of HF
severity. This may be why candesartan is marginally effective in
patients with a moderately preserved ejection fraction.
The most important ﬁnding in the present study is the effect of
azilsartan on diastolic dysfunction: azilsartan decreased the LV E/e0
ratio. The E/e0 ratio seems to be the most reliable parameter toassess cardiac diastolic function9. The E/A ratio and the LV decel-
eration time are also parameters of cardiac dysfunction, although
they are inﬂuenced by the LV loading conditions; therefore, we did
not assess these parameters. The question arises as to what is the
likely mechanism by which azilsartan, but not candesartan, im-
proves LV diastolic dysfunction.
4.2. Azilsartan and candesartan in the improvement of LV diastolic
dysfunction
Our hypothesis was that azilsartan improves cardiac diastolic
function in patients with hypertension. We proved this hypothesis,
but the mechanisms underlying this effect need to be considered.
First, a decrease in the blood pressure may improve cardiac
M. Sakamoto et al.204diastolic function. However, this was not the circumstance because
candesartan, which did not improve cardiac diastolic function,
decreased the blood pressure to levels comparable to those in the
azilsartan group. Second, a decrease in the heart rate may improve
cardiac diastolic function. Azilsartan but not candesartan indeed
signiﬁcantly decreased the heart rate. The mechanisms may be
attributable to the effects of coadministered drugs such as Ca
channel blockers or to the direct effects of azilsartan; however, the
mechanisms remain unclear. This possible mechanism cannot be
denied because decreases in the heart rate may affect LV diastolic
properties by increasing the LV relaxation rate. Third, pharmaco-
logical actions speciﬁc to azilsartan may affect the myocardium
such as reversing remodeling; changes in the LV end-diastolic
volume and end-systolic volume alter the LV relaxation rate22.
However, the present study revealed that neither end-diastolic
volume nor end-systolic volume had changed at 3e6 months.
Myocardial ﬁbrosis, which affects the LV diastolic pressureevolume
relationship and, consequently, cardiac dysfunction, may be
affected by azilsartan. The chemical structure of azilsartan is very
similar to that of candesartan10,20, which is difﬁcult to believe
considering it has speciﬁc effects onmyocardial ﬁbrosis. Fourth, the
only difference between azilsartan and candesartan is the strength
of their afﬁnity to angiotensin II receptors and their afﬁnity to the
arterial vasculature23,24. Compared to candesartan, azilsartan has a
higher afﬁnity for angiotensin II receptors and a higher afﬁnity for
vasculature because of the difference of one residue in the molec-
ular structure24. The effects on the arterial vasculature may affect
the LV relaxation rate22,25; this effect increases the capacitance of
the aorta and delays the onset of ejection, and thus increases the LV
relaxation rate22,25. In the present study, we did not measure aortic
capacitance, but differences in the aortic diastolic pressure may
reﬂect changes in the aortic capacitance. We could not identify the
exact hemodynamic mechanisms, although it would be plausible to
say that azilsartan improves cardiac diastolic function, whereas
other ARBs, including candesartan, do not.
4.3. Clinical importance
The number of patients with HFpEF is increasing progressively
with a prognosis as poor as that of HFrEF2,3. The prognosis of
patients with HFpEF has not improved, whereas the prognosis of
patients with HFrEF has improved; there is consequently an urgent
need to ﬁnd suitable drugs for patients with HFpEF2,3. There are no
effective drugs for HFpEF, including ordinary ARBs and aldosterone
blockers. This study indicates that azilsartan is a potentially good
candidate for patients with HFpEF. If azilsartan improves diastolic
function and cardiovascular outcomes such as cardiovascular death
or hospitalizations due toHF, itmay be theﬁrst drug to treat patients
with HFpEF. However, a large-scale clinical trial using azilsartan in
patients with HFpEF is deﬁnitely required in the near future.
Another important clinical implication of the present study is
that clinicians need to pay attention to vascular insufﬁciency in
addition to myocardial stiffness in patients with HFpEF. If treating
vascular insufﬁciency and improving myocardial remodeling can
improve cardiac diastolic function, then such patients should be
treated with ARBs, ACEs, and/or calcium channel blockers because
calcium channel blockers improve vascular damage26. In addition
to azilsartan, the combination of ARBs and Ca channel blockers may
be a candidate for patients with HFpEF.
4.4. Study limitations
The present study has several limitations. First, it was an open-
label trial with a small sample size. However, to decrease this
limitation, we used the objective end-point of the LV E/e0 ratio.Second, the severity of HF pathophysiology may differ between
retrospective and prospective studies. Therefore, we enrolled all HF
patients with hypertension who received azilsartan in our depart-
ment, which resulted in the absence of selection bias.
Third, because azilsartan can also be used to treat hypertension,
an improvement in LV E/e0 may be attributable to a decrease in high
blood pressure. However, this does not seem to be the circumstance
because lowering the blood pressure using candesartan did not
improve cardiac diastolic function. This suggests that the decrease
in the LV E/e0 ratio is attributable to azilsartan-speciﬁc pharmaco-
logical actions, and not the secondary effects of decreased blood
pressure.
In summary, despite these limitations, we propose the hy-
pothesis that azilsartan improves cardiac diastolic function in HF
patients with hypertension. Further large-scale trials are required
to verify the beneﬁcial effects of azilsartan in HF patients.Acknowledgments
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